CIPLA vs SUNPHARMA: Stock Comparison
SUN PHARMACEUTICAL IND L is the larger company by market capitalisation. CIPLA shows a lower P/E, a higher dividend yield and lower leverage, while SUN PHARMACEUTICAL IND L shows a higher ROE, faster revenue growth and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
CIPLA leads 7; SUNPHARMA leads 6 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | CIPLA | SUNPHARMA |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | CIPLA | SUNPHARMA |
|---|---|---|
| Live Price | ₹1,420 | ₹1,913.3 |
| Day Change | 1.23% | 0.73% |
| Volume | 5.33 L | 11.08 L |
| 52-Week High | ₹1,673 | ₹2,046.9 |
| 52-Week Low | ₹1,165.7 | ₹1,548 |
| Distance from 52W High | -15.12% | -6.53% |
Valuation
| Metric | CIPLA | SUNPHARMA |
|---|---|---|
| Market Cap | ₹1.14 L Cr | ₹4.59 L Cr |
| P/E Ratio | 34.03x | 37.7x |
| P/B Ratio | 3.33x | 5.46x |
| EPS | ₹10.67 | ₹4.65 |
| Book Value | ₹426.25 | ₹348.31 |
| Dividend Yield | 0.91% | 0.83% |
Growth
| Metric | CIPLA | SUNPHARMA |
|---|---|---|
| Revenue Growth (TTM YoY) | -2.1% | 12.8% |
| EPS Growth (TTM YoY) | -54.6% | 25.6% |
| Qtr Sales Growth | -28.68% | -62.48% |
| Qtr Profit Growth | 9.75% | -61.56% |
Profitability & Leverage
| Metric | CIPLA | SUNPHARMA |
|---|---|---|
| ROE | 11.19% | 13.72% |
| ROCE | 11.58% | 15.12% |
| Net Margin | 13.96% | 18.56% |
| Operating Margin | 18.74% | 26.44% |
| Debt to Equity | 0.01x | 0.05x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | CIPLA | SUNPHARMA |
|---|---|---|
| Promoter Holding | 9.17% | 54.48% |
| FII Holding | 20.21%▼ 2.35 pp | 14.53%▼ 1.4 pp |
| DII Holding | 34.63%▲ 2.66 pp | 22.18%▲ 1.07 pp |
| Public Holding | 15.94%▼ 0.31 pp | 8.81%▲ 0.33 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: CIPLA and SUN PHARMACEUTICAL IND L.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.